undamentalytics Newsletter
Sign in

Assembly Biosciences, Inc. cash flow statement

In fiscal 2025, Assembly Biosciences, Inc.'s operations generated −$41.1m of cash; it spent $66,000 on capital projects, leaving free cash flow of −$41.2m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−352−65−84−63−93−8423−51−41−38
Depreciation and amortisation00101000000
Stock-based pay59282122575357
Capital spending01020300000
Free cash flow−351−65−86−63−96−8522−51−41−39
Free cash flow after stock pay−40−8−94−106−85−102−9117−54−46−45
Shares issued—6515513555305220

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ASMB vs CGENASMB vs VRDNASMB vs WVE

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Assembly Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Assembly Biosciences, Inc.